Brief: Crispr Therapeutics And Maxcyte Expand Clinical And Commercial License Agreement Into Oncology

MaxCyte

09/11/2018 12:06

Nov 9 (Reuters) - CRISPR Therapeutics AG  CRSP.O :
    * CRISPR THERAPEUTICS AND MAXCYTE EXPAND CLINICAL AND
COMMERCIAL
LICENSE AGREEMENT INTO ONCOLOGY
    * CRISPR THERAPEUTICS AG - WILL OBTAIN NON-EXCLUSIVE
DEVELOPMENT
AND COMMERCIAL-USE RIGHTS TO MAXCYTE'S CELL ENGINEERING PLATFORM
    * CRISPR THERAPEUTICS - GAINS ADDITIONAL RIGHTS TO MAXCYTE'S
CELL
ENGINEERING TECHNOLOGY TO DEVELOP CRISPR/CAS9-BASED CELL
THERAPIES IN IMMUNO-ONCOLOGY
    * CRISPR THERAPEUTICS AG - MAXCYTE WILL RECEIVE MILESTONE
AND
SALES-BASED PAYMENTS IN ADDITION TO OTHER LICENSING FEES

Source text for Eikon:  ID:nGNX5RlXBD 
Further company coverage:  CRSP.O 

 ((Reuters.Briefs@thomsonreuters.com;))